Glioblastoma (GBM) represents the most aggressive and lethal form of primary brain cancer. We now know that GBM contains small subsets of cells that display tumor-propagating stem-like phenotypes (GBM stem cells, GSCs) that act as critical determinants of GBM resistance to current treatments and tumor recurrence. Understanding and ultimately targeting the epigenetic mechanisms that induce and maintain these tumor- propagating cell subsets is critical to improving GBM therapy and patient outcomes. Altered patterns of DNA methylation are widely reported in human GBM. However, substantial knowledge gaps remain in our understanding of the molecular mechanisms responsible for this epigenetic dysregulation, its downstream consequences and role in the tumor propagating GSC phenotype. This proposal builds on our published and preliminary findings that oncogenic reprogramming transcription factors induce tumor propagating GBM stem cells by regulating miRNA networks that target determinants of DNA methylation. Our new preliminary data implicate a previously unrecognized Sox2:miR-10b-5p:Tet2 axis by which Sox2 induces onco-miR10b-5p that represses the Tet2 demethylase in GBM cells. This axis decreases the conversion of 5-methylcytosine to 5- hydroxymethylcytosine (5hmC), the reaction catalyzed by TET (Ten Eleven Translocation) proteins and a key intermediate step in DNA de-methylation. The potential significance of this axis on oncogenic transcriptome generation is supported by clinical data showing that miR-10b-5p expression is substantially elevated in GBM, that low Tet2 and low 5-hmc expression correlate with poor prognosis in GBM patients, and that Tet2 knock- down accelerates the invasive growth of GBM xenografts. This proposal will test the hypothesis that Sox2 drives tumor-propagating GSCs by activating onco-miR-10b-5p that represses Tet2 resulting in an oncogenic DNA methylome and transcriptome. These goals will be achieved through the following specific aims: (i) Determine how the Sox2:miR-10b:Tet2 axis modifies the DNA methylation landscape of GSCs; (ii) Determine how enzymatic and non-enzymatic functions of Tet2 regulate GSCs; (iii) Determine the potential to treat GBM in vivo by inhibiting Tet2 down-regulation by miR-10b-5p. Successful execution of the proposed research plan will fill critical gaps in our understanding of epigenetic molecular events by which reprogramming transcription factors induce tumor propagating cells in GBM through transcriptional silencing, and establish the potential to treat GBM by targeting this novel axis that alters the tumor transcriptome via Tet2 inhibition.

Public Health Relevance

Glioblastoma tumor-propagation requires stem-like tumor cells that are self-renewing, multi-potent, and resistant to cytotoxic therapeutics. These tumor-propagating cells are maintained by reprogramming transcription factors that alter transcriptional programs via epigenetic mechanisms. These epigenetic mechanisms that drive tumor propagating glioblastoma cells and their potential for therapeutic targeting remain only partially defined. The studies in this proposal are focused on understanding how the ten-eleven translocation-2 deoxygenase (Tet2) and Tet2-dependent methylome modulation regulate glioblastoma cell stemness and tumor propagation and on testing strategies for targeting these mechanisms to treat glioblastoma.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS110087-01A1
Application #
9817100
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Fountain, Jane W
Project Start
2019-08-01
Project End
2024-05-31
Budget Start
2019-08-01
Budget End
2020-05-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Hugo W. Moser Research Institute Kennedy Krieger
Department
Type
DUNS #
155342439
City
Baltimore
State
MD
Country
United States
Zip Code
21205